Immune-mediated kidney diseases will lead talks at Nexus Berlin 2016
Drug development has dramatically improved the outcome of diseases in most medical disciplines. However, this does not seem to be the case in nephrology. This will be discussed in two weeks’ time when the ISN Nexus symposium will take place in Berlin, Germany from April 14 to 17, 2016.
Despite enormous research efforts carried out by the basic science kidney research community, only few drug targets have been successfully validated and developed into innovative drugs for patients.
This will be the first ISN Nexus meeting on immune-mediated kidney diseases. “We are living in exciting times of drug development, and as clinicians we see improvements all around us,” explains ISN Nexus Berlin Co-Chair Hans-Joachim Anders.
Introduced in 2006, ISN Nexus Symposia bridge the gap between basic research and clinical practice by offering a profound focus on translational medicine and clinical application. The objective is to promote interaction, collaboration and to accelerate the advancement of applied science in this area, which ISN Nexus Berlin Co-chair David Jayne, believes is of “direct value to our patients in regular clinical practice.”
Head to the Nexus Berlin website to get the latest on the program, speakers, sessions and more.
